Business
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of
About this update from Ptc Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors. Ms. Chutter is a highly accomplished biotechnology investment banker with an extensive list of achievements over her long tenure at Morgan Stanley, including building and leading the bank's biotechnology franchise. \n\"I have closely followed Jessica's illustrious career, and I am proud to welcome her to PTC's Board of Directors,\" said Michael Schmertzler, Chairman of the Board of Directors. \"Jessica will play an integral role as the Board continues to work with the management team on charting the company's next stage of growth.\"Ms. Chutter recently retired as Managing Director and Chair of Biotechnology Investment Banking of Morgan Stanley after a distinguished career spanning over 40 years. She helped build the biotechnology banking practice at Morgan Stanley and is widely considered a pioneer in establishing the field of biotechnology investment banking. During her tenure at Morgan Stanley, Ms. Chutter was involved in approximately $80 billion of capital raising and $85 billion of strategic transactions. Ms. Chutter earned a BA in Commerce/Economics from McGill University and an MBA from Harvard University.\"We look forward to Jessica's contributions as we continue to build the PTC of the future,\" said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. \"Jessica was a trusted advisor to PTC during her time at Morgan Stanley and her broad vision, extensive biotech experience and track record of successful company building will make her a valued Board member.\"\"I have been impressed with the transformation of PTC over the past few years into a strong and execution-oriented biotech company well positioned for future success,\" said Ms. Chutter. \"I look forward to working with Matt, Michael, and the rest of the PTC Board at this important time in the company's growth.\"About PTC Therapeutics, Inc. PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients ...